Proteomic study of urine to discover novel biomarkers for human prostate cancer. The purpose of this project is to identify novel markers in the urine of patients with prostate cancer. These biomarkers may ultimately prove useful in the development of novel diagnostic tools for the management of this disease.
Proteomic study of tears to discover novel biomarkers for human breast cancer. The purpose of this project is to identify novel markers in the tears of patients with breast cancer. The results from this study may improve the prognosis of breast cancer patients.
Unified platform for real time QA in radiation therapy in brachytherapy based on high resolution silicon detectors (Magic Plate). This project will design and manufacture new devices for measuring the amount of radiation given to the patient during radiotherapy. This will improve the accuracy and safety of cancer treatment as well as greatly reducing the time needed to perform essential safety checks.
Rapid detection of rare-event cells by strong UP-conversion
encoded nano-radiators (SUPER Dots): finding a needle in a haystack. Current diagnostic tests are not sensitive enough to detect cancer in its very early stages or early recurrence following treatment. The new technologies developed by this project will be able to find single cancer cells in blood and urine samples heralding a new era in medical diagnostics.
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE120100006
Funder
Australian Research Council
Funding Amount
$600,000.00
Summary
An adaptable and dedicated linear accelerator for medical radiation research. Leading radiation scientists developing innovative methods and devices for treating cancer patients will collaborate in future research using this highly adaptable linear accelerator for medical radiation research. Innovations in tumour targeting, better patient safety, new medical devices and improved cancer outcomes are expected.
Understanding endocrine tumorigenesis - opportunities for new diagnostics and therapies. This project will generate new knowledge significant for improving cancer diagnosis and designing new therapies for cancer patients as we embrace the personalised medicine era. Specific focus is on endocrine tumours. This research has as its aim improved survival for people diagnosed with cancer.
Targeting the delivery of cytotoxic agents to tumour cells using novel minicells as drug delivery vehicles and engineered, bispecific antibodies. Cancer persists as a major cause of morbidity and mortality globally. A major problem is the non-specific action of drugs used for treatment. The minicell is a drug delivery vehicle, capable of packaging a variety of drugs. The project will develop tumour-specific antibodies that will target minicells to tumours, improving cancer survival rates.
A phenomenological approach to improve radioembolisation treatment of cancer. In recent years, radioembolisation for liver cancer has become an effective therapeutic option. However, it is likely that patients are being “under-treated” as doses remain based on results from external radiation therapy. This project will develop a phenomenological approach to radionuclide therapy to improve outcomes for cancer patients.
A novel DNA damage repair protein as a regulator of DNA double strand break repair and genome integrity. This project aims to define the function of a novel DNA damage repair protein. These data will provide a better understanding of DNA repair biology and may reveal novel diagnostic and treatment options for many diseases associated with DNA repair defects, including cancer.
Roles of the kynurenine pathway in physiological and pathological brain function. This project will aim to study the metabolism of the essential amino acid tryptophan in the brain and its involvement in diseases including multiple sclerosis and brain tumours.